Clinical Trials | May 28, 2024
Ascentage releases results from multiple clinical studies of its lead drug candidates
These abstracts report on the company's three lead drug candidates, including olverembatinib
These abstracts report on the company's three lead drug candidates, including olverembatinib
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
_256_384.jpeg)
ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Additional data from APPRAISE ATP trial reinforce modular therapy approach
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Subscribe To Our Newsletter & Stay Updated
